Anette Weyergang viser PCI-teknologien til Erna Solberg. Foto: Oslo Cancer Cluster Innovasjonspark

Radforsk bevilger 4,5 millioner kroner til kreftforskning

Siden oppstarten i 1986 har Radforsk kanalisert 200 millioner kroner av overskuddet tilbake til kreftforskning ved Oslo universitetssykehus.


Radforsk will distribute resources to photodynamic therapy and photochemical internalization (PDT/PCI) related research.

Our portfolio company OncoImmunity receives €2.2 million

OncoImmunity receives €2.2 million to roll out its machine-learning platform to enable the development of personalized cancer immunotherapies.

Nordic Nanovector receives Promising Innovative Medicine Designation

This acknowledges the potential of Betalutin® to offer therapeutic benefits to patients with follicular lymphoma, says CMO Lisa Rojkjaer in a press release.

Om Vaccibody i NRK EKKO

NRK EKKO med innslag om vår porteføljebedrift Vaccibody.

Targovax: Reports full data set on clinical trial of cancer vaccine TG01

Our portfolio company Targovax reports encouraging disease-free survival (DFS) data from TG01 trial in resected pancreatic cancer: 16.1 months median DFS with TG01 and gemcitabine combination for all 32 patients in the trial 19.5 months DFS in 2nd cohort who received an optimized dosing regimen 94% of patients had mutant RAS specific adaptive immune activation […]

Vaccibody: First 10 patients enrolled and vaccination started

Our portfolio company Vaccibody has released an update on the clinical trial of their neoantigen cancer vaccine in phase I/II: 10 patients have been enrolled and vaccination has started.   Mads Axelsen, MD, Chief Medical Officer in Vaccibody, said in a press release: “We are very pleased with the enrollment in the neoantigen trial and […]

Targovax: Encouraging interim results of ONCOS-102

Our portfolio company Targovax has released interim results from the phase I trial of ONCOS-102 in checkpoint inhibitor refractory melanoma.   Dr. Magnus Jäderberg, CMO of Targovax, said in a press release from the company: “Given the limited number of patients who have completed the study to date, it is encouraging to already see a complete […]

Vaccibody in collaboration with prestige company Nektar Therapeutics

Our portolio company Vaccibody AS just entered a clinical collaboration with U.S. company Nektar Therapeutics.   The aim of the collaboration is to evaluate Vaccibody’s personalized cancer neoantigen vaccine, VB10.NEO, in combination with Nektar’s immune treatment NKTR-214, which is a CD-122-biased agonist. In an interview with Norwegian financial paper “Finansavisen”, President and CSO  in Vaccibody, […]